Filter posts

2014 BIO Investor Forum Fireside Chat with Nick Leschly and Chris Collins

Nick Leschly has served as bluebird bio’s president and chief executive officer since September 2010. …

T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets

New approaches in cancer immunology are achieving promising early-stage results through novel techniques for arming …

Biotech Analyst Optimism: Price Targets Post-IPO

In a recent blog post, Bruce Booth of Life Sci VC, writes about the relationship …

Beggar-Thy-Neighbor Medicine: Wall Street Journal Op-Ed

In an editorial about specialty drug prices, the Wall Street Journal writes: “To understand how …

The Cancer Death-Panel App

In an article for the New York Post, Robert Goldberg, vice president of the Center …

#BIO2014 Blogger Roundup

Want to know what’s happening at the 2014 BIO International Convention? Find out from our …

#BIO2014 Blogger Roundup

Want to know what’s happening at the 2014 BIO International Convention? Find out from our …

#BIO2014 Blogger Roundup

Want to know what’s happening at the 2014 BIO International Convention? Find out from our …

Liking, Sharing, and Tweeting to Better Health

Making an impact online goes beyond having a Facebook page. Helping to open the 2014 …

#BIO2014 Blogger Roundup

Want to know what’s happening at the 2014 BIO International Convention? Find out from our …